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Copper transporter 1 (CTR1) is a transmembrane protein that imports copper(I) in yeast and mammalian cells. Surprisingly, the protein 
also mediates the uptake of platinum anticancer drugs, e.g. cisplatin and carboplatin. To study the effects of several metal-binding 
residues/motifs of hCTR1 on the transport of both Cu+ and cisplatin, we have constructed Hela cells that stably express a series of 
hCTR1 variant proteins including H22-24A, NHA, C189S, CT178, H139R and Y156A, and compared their abilities to regulate the 
accumulation and cytotoxicity of these metal compounds. Our results demonstrated that the cells expressing the hCTR1 mutants of 
histidine-rich motifs in the N-terminus (H22-24A, NHA) resulted in a higher basal copper level in the steady state compared to those 
expressing wild-type protein. However, the cellular accumulation of both copper and cisplatin in these variants was found on a  similar 
level to that of wild type when incubated with excess amounts of metal compounds (100 μM). The cells expressing hCTR1 variants of 
H139R and Y156A exhibit lower capacities towards accumulation of copper but not cisplatin. Significantly, cells with the C189S 
variant partially retained the ability of the wild-type hCTR1 protein to accumulate both copper and cisplatin, while cells expressing C-
terminus truncated variant of hCTR1 (CT178) absolutely abolished this ability, suggesting that this motif is crucial for the function of 
the transporter.  
Introduction 
Copper is an essential element for life. The reversible oxidation 
from Cu+ to Cu2+ renders its function as a critical cofactor for a 
variety of cellular process from oxidative phosphorylation, iron 
metabolism, free radical detoxification, neurotransmitter 
synthesis to connective tissue maturation.1, 2 However, excess 
copper exhibits toxic effects as a result of generating reactive 
oxygen species which could damage the cellular components, 
including protein and DNA.3, 4 Therefore, the copper homeostasis 
has to be tightly regulated to avoid toxic effects. All organisms 
from yeast to humans have developed sophisticated mechanisms 
by which the cellular accumulation, distribution and 
detoxification of copper are properly controlled.5, 6 Malfunctions 
of copper relevant translation may cause diseases such as 
neurodegenerative diseases7 and two inherited diseases, i.e. 
Wilson’s and Menkes’ diseases, which were attributed to copper 
hyperaccumulation and deficiency respectively.8   
 Although the cellular copper uptake can be carried out by 
divalent metal transporter 1 (DMT1),9 the majority of copper 
acquisition is mediated by copper transporter 1 (CTR1),10 which 
transports cuprous copper (Cu+). Extracellular copper was 
suggested to exist with an oxidation state of +2 and reduced to 
Cu+ probably by membrane-associated reductases prior to 
translocation across the cellular membrane via CTR1.11 CTR1 is 
a membrane protein with three transmembrane domains, an 
extracellular N-terminus and an intracellular C-terminus. Three 
monomers of CTR1 form a channel-like pore, through which Cu+ 
is transferred across the membrane probably via a series of trans-
chelation reactions between sulfur- (Met and Cys) or nitrogen- 
(His) containing residues located at the inner face of the pore.12-14 
In addition to CTR1, the low affinity copper transporter CTR2, 
which mainly located intracellularly with a small fraction on 
plasma membrane, may account for some of the copper import.15  
 Copper transporter 1 (hCTR1) was also found to modulate the 
influx of Pt(II) based anti-cancer drugs such as cisplatin and 
carboplatin.16, 17 Elevated expression levels of human CTR1 
(hCTR1) in the human ovarian carcinoma cell were associated 
with increased cellular uptake of cisplatin, especially at the initial 
stage.18 Similar to copper, cisplatin also rapidly down-regulated 
hCTR1 in cultured human ovarian carcinoma cells by inducing 
internalization of the protein from the plasma membrane, which 
may contribute to the resistance of the drug.19 In spite of the 
importance of CTR1 protein in the uptake and resistance of 
cisplatin, the molecular details of CTR1–mediated cisplatin 
transport remain unclear. Considering both Cu(I) and Pt(II) are 
soft acids which shares same preference on the binding to soft 
ligands including methionine, such a residue on hCTR1 may be 
important for the transport of both Cu+ and cisplatin. Indeed, 
previous studies indicated that deletion of either the N-terminus 
of hCTR1 (amino acids 1-45) or the 40MXXXXM45 motif 
eliminated the ability of hCTR1 to transport copper and partially 
reduced the capacity to transport cisplatin.20 The Met-rich motif 
(150MXXXM154) located at the second transmembrane domain 
(TM2) was also shown to be critical for copper transport.21 
However, the role of this methionine(Met)-rich motif on cisplatin 
transport was contradictively reported: Mutations of Met150 and 
Met154 absolutely abolished the ability of exogenous hCTR1 to 
stimulate cisplatin uptake in small cell lung cancer cells 
(SCLC).22 On the contrary, cisplatin uptake was significantly 
enhanced in hCTR1-variant-transfected mouse embryo 
fibroblasts in which both alleles of CTR1 had been knocked out 
(MEF ctr1-/-).23 Furthermore, the fluorescence resonance energy 
transfer (FRET) assay of the interactions between yeast CTR1 
monomers showed that copper enhanced the FRET in a manner 
correlated with cellular copper uptake, while cisplatin did not 
change the FRET.24 Mutation of G167, which is located at the 
third transmembrane domain of hCTR1 and involved in helix 
packing of the protein, impaired cellular uptake of copper but not 
cisplatin.22 These results indicated that although hCTR1 
transports both Cu+ and cisplatin, the underlying machanisms 
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may differ due to the distinct ligand selectivity, reactivity and 
structure-dependence between copper and cisplatin. 
 
Fig. 1 Schematic diagram showing the topology of hCTR1 The 
residues or motifs which have been mutated, are highlighted in magenta. 
All histidine and tyrosine residues were mutated to alanine except H139, 
which was mutated to arginine, while cysteine was mutated to serine. 
 Besides methionine residues, other metal-binding amino acids, 
e.g. histidine and cysteine residues may also play important roles 
in the uptake of copper and cisplatin by hCTR1. To further 
investigate the molecular mechanism of hCTR1-meidated 
transport of these metal compounds, a series of mutant hCTR1 
expressing constructs were made and introduced into Hela cells, 
and  their effects on cellular resistances and accumulation of both 
copper and cisplatin in these stably transfected cells were 
measured and compared. The role of histidine-rich motifs in the 
N-terminus was investigated by mutation of histidine residues in 
H22-24 and H5, 6, 22-24 to alanine (H22-24A and NHA). In one 
hCTR1 variant, His139 in TM2 was mutated to arginine (H139R) 
since this residue was proposed to form stacked rings with 
Met150 and Met154 which provide chelation environment for 
copper transport.13 Two C-terminal variants C189S and CT178 
(Deletion of C-terminal fragment 179KAVVVDITEHCH) were 
constructed to investigate the role of cysteine residue since it is a 
soft ligand and suppose to coordiate with both Cu(I) and Pt(II) 
compounds. Tyr156 is located in the putative extracellular loop 
near TM2. Although not considered as a metal-binding residue, it 
may play a structrual role in copper entry into the transmembrane 
pathway.25 To further elucidate the role of this residue on hCTR1 
function, the Y156A variant was also constructed. All residues 
and motifs selected for mutation study were highlighted in Fig. 1. 
Experimental 
Materials 
Hela cells were purchased from American Type Culture 
Collection (ATCC, Manassas, VA). Cisplatin, carboplain, 
transplatin, fetal bovine serum (FBS) and Geneticin (G418) were 
purchased from Sigma (Sigma-Aldrich) and used withour further 
process. The platinum drugs were dissolved in OPTI-MEM 
medium (Invitrogen) to a final concentration of 10 mM prior to 
usage. Mouse anti-HA primary antibody was obtained from Cell 
Signaling Technology, Inc. (Danvers, MA). Rabbit anti-CTR1 
primary antibody, HRP conjugated anti-mouse and anti-rabbit 
secondary antibody were purchased from Santa-Cruz 
Biotechnology, Inc. RIPA lysis buffer was purchased from Pierce 
Biotechnology. Other chimicals are purchased from either Sigma 
or USB. All water used are from Millipore. 
Construction of wild-type and mutant pcDNA3.1-HA-hCTR1 
expression vectors 
The wild-type full length hctr1 gene was amplified from the 
plasmid harboring human ctr1 cDNA (kindly provided by Prof. 
D.J. Thiele26) by PCR using the forward primer: 5′-
TTATTAAAGCTTATGGATCATTCCCACCATATG-3′ and the 
reverse primer: 5′-TTATTACTCGAGTTACTAATGGCAAT-
GCTCTGTGATATC-3′, by which the Nde І and Xho І restriction 
sites were introduced at the 5′- and 3′-ends of the PCR product, 
respectively. After restriction cleavage, the PCR product was 
inserted into pcDNA3.1-HA vector (a gift from Prof. Marie C.M. 
Lin, the University of Hong Kong), which was digested with the 
same restriction enzymes. All mutant pcDNA3.1-HA-hCTR1 
expression vectors were generated using Phusion Site-Directed 
Mutagenesis Kit (Finnzymes) with primers summarized in Table 
S1. PCR reactions were performed with Phusion hot star high-
fidelity DNA polymerase and with plasmid pcDNA3.1-HA-
hCTR1 as the template (for the NHA mutant, H22-24A was used 
as a template). All plasmids were confirmed to be correct by 
DNA sequencing. 
Cell Culture 
Hela cells were maintained in Dulbecco’s modified Eagle’s 
Medium (DMEM) supplemented with 10% FBS, 100 U/ml 
penicillin G, 100 µg/ml streptomycin, and cultured at 37 oC, 5% 
CO2 incubator. 
Plasmid transfection and establishment of stable cells 
One day prior to transfection, 1×106 cells in 2 ml DMEM medium 
were plated so that cells will be 90% confluent at the time of 
transfection. To make the transfection complex, the plasmid (2 
μg) was diluted with 100 μl OPTI-MEM medium, followed by 
addition of FuGENE HD transfection reagent (4 μl). After 
incubation at room temperature for 15 minutes, the transfection 
complex was added to the cells in a drop-wise manner. An 
enhanced green fluorescent protein (EGFP) expressing plasmid, 
pcDNA3.1-EGFP (a gift from Prof. Marie C.M. Lin, The 
University of Hong Kong) was transfected into the non-
transfected cells under the same conditions, and the transfection 
efficiency was evaluated by monitoring the expression of EGFP 
under fluorescence microscope. 
 To establish stable cells, cells after 24 hours of transfection 
were passaged to fresh DMEM/FBS medium containing 0.7 
mg/ml geneticine (G-418) with the dilution of 1:8. Growth 
medium was renewed every 2-3 days and those dead cells were 
removed. Cells trasfected with different plasmid were cultured in 
the presence of G418 for 3-4 weeks until no more dead cells were 
found and EGFP expression was observed in >95% cells 
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transfected with EGFP expressing plasmid.  
Cell extracts and western blotting 
After washing three times with PBS, the cell pellets were lyzed in 
50-100 μl RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 1% NP-40, 0.25% Na-deoxycholate and 1% cocktail 
protease inhibitor) by vortexing and the supernatant was collected 
by centrifugation (13 000 rpm, 30 min, 4 °C). The total protein 
concentration was determined by BCA protein assay kit 
(Novagen). Total protein extracts (20 μg) were separated over a 
12.5% tris-glycine gel and electro-blotted onto the PVDF 
membrane using the Semi-Dry transfer unit Hoefer TE 77 
(Amersham). The membrane was blocked with TBS-tween (50 
mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20, pH 7.5) 
supplemented with 5% non-fat milk (blocking buffer) at room 
temperature for one hour and then incubated with appropriate 
primary antibody diluted in the blocking buffer at room 
temperature for one hour. After washed with TBS-tween buffer 
for three times for 10 mins each, the blot was incubated with 
corresponding horseradish peroxidase-conjugated secondary 
antibody with shaking at room temperature for another one hour. 
The bolt was washed again with TBS-tween buffer three times for 
10 mins each. The signal was detected by chemiluminescent ECL 
system for horseradish peroxidase. 
Biotinylation of cell surface proteins 
To label the cell surface proteins, biotinylation of cells was 
carried out using the thiol-cleavable, cell-impermeable Sulfo-
NHS-SS-biotin reagent (Pierce). Other than stated, all procedures 
were carried out in ice. Before biotinylation, cells were placed in 
ice for 15 minutes, the culture medium was removed and the cells 
were washed once with DMEM containing HEPES buffer (25 
mM) and three times with PBS containing 1.0 mM MgCl2 and 0.1 
mM CaCl2. Cells were then incubated with 1.27 mM Sulfo-NHS-
SS-biotin reagent dissolved in biotinylation buffer (10 mM 
triethanolamine, 150 mM NaCl, 2 mM CaCl2, pH 7.5) for 30 min. 
Biotinylation was quenched by incubation with glycine (100 mM 
dissolved in PBS with 1.0 mM MgCl2 and 0.1 mM CaCl2) for 30 
min, this step was repeated. Cells were lyzed in a lysis buffer (50 
mM Tris-HCl, 1% Triton-X-100, 150 mM NaCl and 5 mM 
EDTA, pH 7.5) by vortexing for 10 mins followed by incubation 
for one hour. The supernatant was collected by centrifugation (13 
000 rpm, 30 mins, 4 oC). The supernatant (10%) was partially 
retained for protein concentration determination and the rest was 
incubated with streptavidin- agarose (Pierce) at the ratio of 100 μl 
agarose per 900 μl of supernatant at 4 °C for overnight. The 
unbound proteins were removed by centrifugation (500 rpm, 5 
mins, 4 °C) and the agarose was washed three times with lysis 
buffer and twice with wash buffer 1 (50 mM Tris-HCl, 0.1% 
Triton-X-100, 150 mM NaCl and 5 mM EDTA, pH 7.5) and once 
with wash buffer 2 (50 mM Tris-HCl, pH 7.5). Proteins were 
eluted with 150 mM dithiothreitol (DTT) diluted in SDS-PAGE 
loading buffer and separated with SDS-PAGE and hCTR1 variant 
proteins were detected using an anti-HA antibody by western 
blotting as described above. 
Cell survival assay 
Cell proliferation was measured by XTT assay (Roche). Around 
five thousand cells stably expressing variant hCTR1 proteins in 
100 μl growth medium were plated into the wells of a 96-well 
tissue culture plate. After overnight incubation, cells were 
exposed to the drugs of different concentrations. To measure cell 
sensitivities towards cisplatin, cells were cultured in 100 μl 
OPTI-MEM medium containing 0-400 μM cisplatin for 10 mins. 
Subsequently, the drug containing cultural medium with the drug 
was removed and the cells were washed once with pre-warmed 
PBS and further cultured in 100 μl fresh culture medium for 
another 4-5 days. To measure cell sensitivities towards CuSO4, 
cells were continually cultured in 100 μl OPTI-MEM medium in 
the presence of different concentrations of CuSO4 (0-200 μM) for 
96 hours. And the medium with the metal ion was then removed 
and the cells were washed once with pre-warmed PBS and further 
cultured in 100 μl fresh culture medium for another 24 hours.  
 To prepare the XTT labeling mixture (Cell Proliferation Kit 
II), XTT labeling reagent was mixed with the electron-coupling 
reagent at 50:1 immediately prior to usage. XTT labeling mixture 
(50 μl) were added to each well and incubated at 37 °C for 4-24 
hours. The absorbance at 495 nm was measured with a reference 
wavelength at 695 nm. The survival curve was generated by 
plotting the absorbance (A495-A695) versus the metal 
concentrations. 
Cellular metal ions accumulation 
Cells stably expressing variant hCTR1 proteins were seeded in 6-
well plates one day prior to the expreiment. After 24 hours, cells 
were exposed to either CuSO4 (100 μM) for 1 hour or platinum-
containing agents (cisplatin, transplatin or carboplatin, 100 μM) 
for 10 mins by the addition of metal/drug containing OPTI-MEM 
medium. The medium was removed after incubation and cells 
were washed three times with ice-cold PBS. Cells were colleted 
and washed with ice-cold PBS once. For each sample, half of the 
cells were lyzed using RIPA buffer and the total protein 
concentration was measured by BCA protein assay kit. The 
remaining cells were digested with 65% nitric acid (50 μl) at 65 
°C for overnight to thoroughly dissolve all cellular debris. The 
mixture was diluted in the following day with buffer containing 
0.1% Triton X-100, 1.4% nitric acid and 2 ppb Tl. Metal 
concentrations were determined by inductively coupled plasma 
mass spectroscopy (ICP-MS, 7500a Agilent technologies) and 
were normalized with total protein concentration. 
Results and discussion 
HA-hCTR1 Expression in Transfected Cells 
The effects of the wild-type and hCTR1 mutants on cellular 
uptake and toxicity of copper and platinum-containing drugs were 
investigated using cisplatin-sensitive Hela cell line.27 A series of 
stably transfected Hela cell lines harboring the wild-type or 
mutant hCTR1 including H22-24A, NHA, H139R, Y156A, 
C189S and CT178 were established. An HA-tag was added to the 
N-termini of these proteins to facilitate the detection of proteins 
by Western blot. The expression of exogenous hCTR1 in the 
stably transfected cells was confirmed by western blot using 
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antibodies against the HA-tag and the internal region of human 
CTR1 (Fig. 2). A band migrating at ~ 40 kDa was detected by 
both anti-HA and anti-CTR1 antibodies corresponding to hCTR1 
expressed from the transfected plasmid. This is in agreement with 
previous reports28, 29 that hCTR1 was N- and O-glycosylated at 
Asn-15 and Thr-27 respectively, with a molecular weight of ca. 
37 kDa for the mature protein. Therefore, the exogenous HA-
hCTR1 expressed from the introduced plasmids was successfully 
glycosylated. 
 
 
Fig. 2 Western blot analysis of exo-hCTR1 expressed in total cell 
lysates (A) and cell surface (B) The antibody against the β-subunit of 
Na+, K+-ATPase was used as the loading control and marker for 
membrane fraction. 
 As shown in Fig. 2B, the successful biotinylation of hCTR1 
proteins indicated that both the wild-type and different mutants of 
hCTR1 were correctly localized on the plasma membrane, as was 
the β-subunit of Na+/K+-ATPase, a plasma membrane marker. 
The expression levels of hCTR1 variants were comparable to the 
wild-type protein and also migrated at ~ 40 kDa, corresponding to 
the HA-tagged monomer as observed previously.30, 31 Based on 
these studies, we found that all the residues or motifs examined in 
this study are not critical determinants for the correct cellular 
distribution of hCTR1. 
hCTR1 Regulation of Copper Uptake and Cytotoxicity 
The basal copper level was tested by incubation of cells 
transfected with hCTR1 variant plasmids in DMEM medium in 
the presence of ca. 0.3 μM copper ions. The basal copper level in 
hCTR1-transfected cells was found to be 2.4-fold higher than that 
in the empty vector transfected cells as shown in Fig. 3A, in 
agreement with previous studies that over-expression of hCTR1 
in mammalian cells stimulated copper uptake.21, 32 Hela cells 
expressing hCTR1 variants of H139R reduced basal copper levels 
by 22% with regards to that in the wild-type protein expressed 
cells (Hela/hCTR1). Deletion of the C-terminal fragment 
179KAVVVDITEHCH exhibits similar effects to the C189S and 
Y156A variant in terms of copper uptake, which reduced basal 
copper levels by ~60%. Unexpectedly, the basal copper 
accumulation levels in the cells expressing the N-terminal 
variants increased by 1.2-fold and 1.5-fold for H22-24A and 
NHA respectively in comparison with that in the wild-type 
hCTR1 expressed cells (Fig. 3A). 
 To measure the rates of copper accumulation, cells transfected 
with variant hCTR1 expressing vectors were exposed to 100 μM 
CuSO4 for 1 h. Similar to basal copper accumulation experiment, 
the cells expressing the wild-type hCTR1 enhanced copper 
uptake by 2-fold compared with the empty vector transfected 
cells (Fig. 3B). The cells expressing the H139R and Y156A 
variants reduced the rates of copper accumulation by 34% and 
39%, respectively. Deletion of the 12 amino acids in the C-
terminus (179KAVVVDITEHCH) disrupted copper transport, 
whereas the single mutation of Cys189 retained 83% capacity of 
copper transport. However, the copper accumulation in the H22-
24A and NHA expressing cells are only slightly higher than that 
in the wild-type protein transfected cells. 
 To examine the expression of hCTR1 variants on the cellular 
sensitivity towards copper toxicity, the IC50 values of CuSO4 in 
these transfected cells were further measured by the XTT method. 
Cells were exposed to increasing concentrations of CuSO4 for 96 
hrs prior to measurement. The cells expressing the wild-type 
hCTR1 was 4.3-fold more sensitive to copper than those cells 
transfected with an empty vector (IC50 16.1 μM versus 69.4 μM, 
Fig. 3C and 3D). Cells expressing the H22-24A and NHA 
showed slightly more sensitive to copper than the wild-type 
hCTR1 expressed cells, with IC50 of 14.3 and 10.6 μM, 
respectively. Mutations of either His-139, Tyr-156 and Cys-189 
reduced the cell sensitivities towards copper, indicating that  
these residues in hCTR1 are important for copper transport. 
Among all hCTR1 variants, truncation of C-terminus (CT178) 
rendered the transfected cells the most insensitive for copper 
accumulation, in agreement with our pervious results that the 
deletion of the C-terminal disabled copper uptake. Theses results 
clearly demonstrated that higher copper accumulation in hCTR1 
variant transfected cells would lead to higher cytotoxicity. 
 
 
Fig. 3 Effects of mutations of hCTR1 on copper uptake and 
sensitivity towards the cytotoxicity of copper in Hela cells (A) Total 
basal copper accumulation in cells cultured in DMEM. (B) Total copper 
accumulation upon exposure to 100 μM CuSO4 for 1 hour. (C) Survival 
rates of Hela cells harboring empty vector (); the wild-type hCTR1 (); 
H22-24A (▲); NHA (▼); H139R (); Y156A (◄); C189S (►) and 
CT178 (), after 96 h continuous exposure to increasing concentrations 
of CuSO4 (20 μM -200 μM). (D) IC50 of CuSO4 with Sigmoidal fitting. 
Error bars represent standard derivations from four independent 
experiments. The asterisk (*) indicates p<0.05 as determined by the 
Student's t test, compared with the wild-type hCTR1. 
 Based on the result above, it seems the His-139, Tyr-156 and 
Cys-189 residues were partially involved in the transport of Cu+ 
ions, while the intact C-terminus is crucial for the normal 
function of hCTR1 on copper transport. However, the role of two 
His-rich motifs (3HXHH and 22HHH) at the N-terminus of 
hCTR1 in uptake of copper of basal and excess level seems 
controversial. Hela cells expressing variants of H22-24A and 
NHA, especially NHA, exhibited obviously higher basal copper 
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accumulation compared with cells expressing the wild-type 
hCTR1, while no such effect was observed when extra copper 
ions (100 μM) were added to the cultural medium. It was 
believed that the extracellular free or protein bound Cu2+ ions 
were reduced by unidentified reductases or reducing agents (e.g. 
ascorbate) at the cell surface to Cu+ prior to being transferred 
across the membrane via hCTR1. Our preliminary study showed 
that Cu2+ bound to hCTR1 via the two His-rich motifs with 
moderate affinity (Kd =9.8 μM) (unpublished data). It is likely 
that at lower copper concentrations (DMEM contains ~ 0.3 μM 
Cu), binding of Cu2+ to the His-rich motifs might inhibit the 
reduction of Cu2+ to Cu+ and subsequently reduce the 
accumulation of copper in cells. Under copper replete conditions, 
the excess copper would result in the system less sensitive 
towards the effects of the His-rich motifs.  
Effects of hCTR1 on Initial Influx of Platinum-based Drugs 
The effects of hCTR1 on the influx of platinum containing drugs 
were examined similarly by comparing the cellular platinum 
accumulation between Hela and Hela/hCTR1 cell lines. Since the 
major contribution of hCTR1 to cisplatin uptake occurred in the 
initial phase of cisplatin influx,33 here we determined the initial 
influx of platinum drugs by exposing cells to cisplatin, 
carboplatin or transplatin at the concentration of 100 μM for 10 
mins. The cell associated platinum contents were measured by 
ICP-MS and the results were summarized in Fig. 4. Hela cells 
expressing exogenous hCTR1 resulted in a 2.2-fold increase in 
platinum accumulation compared with cells transfected with an 
empty vector under identical conditions. Such effects are even 
more pronounced for carboplatin, i.e. a 2.9-fold increase of 
platinum contents in Hela cell was observed due to the expression 
of exogenous hCTR1. In contrast, the platinum contents were 
almost the same for the two types of cells when exposed to 
transplatin, indicating that hCTR1 did not stimulate the cellular 
accumulation of transplatin. The initial influx of transplatin in 
Hela/hCTR1 cells is 1.1-fold higher than that of cisplatin, while 
the initial influx of carboplatin is 58% of that of cisplatin. Our 
results demonstrated that transplatin entered cells via hCTR1-
independent pathway, in agreement with a previous report that re-
expression of hCTR1 in mouse embryo fibroblasts ctr1-/- cells did 
not stimulate the cellular accumulation of transplatin.23 
 
Fig. 4 Pt-associated with Hela cells transfected with an empty vector 
or hCTR1 expression vector, error bars represent standard 
derivations from six separate cultures. The asterisk indicates p<0.05 as 
determined by the Student's t test.  
hCTR1 Regulation of Cisplatin Uptake and Cytotoxicity 
The effects of the expression of hCTR1 variant proteins on the 
initial influx of cisplatin in Hela cells were examined by exposing 
cells to 100 μM cisplatin for 10 min and the cell associated 
platinum contents were measured. As shown in Fig. 5A, C189S- 
transfected cells significanly inhibited platinum uptake with 42% 
of the incremental increase in platinum content produced by the 
wild-type hCTR1. Notably, C-terminal truncation (CT178) 
impaired the cisplatin transport function of hCTR1 (Fig. 5A), 
whereas the platinum content increased by 1.1-fold compared 
with that for the empty vector transfected cell, or 7.3% of the 
incremental increase in that produced by the wild-type hCTR1. 
However, it was found that cells expressing either of hCTR1 
variants of H22-24A, NHA, H139R and Y156A preserved 
cisplatin transport function of hCTR1. 
 The effects of 10 mins exposure to increasing amounts of 
cisplatin on the growth rate of Hela cells transfected with hCTR1 
variant plasmids during a subsequent period of 4 days were 
investigated (Fig. 5B). As expected, the expression of the wild-
type hCTR1 increased the sensitivity of Hela cells to cisplatin by 
a factor of 2.1-fold, with the IC50 decreased from 193.1±9.6 to 
92.4±5.9 μM (Fig. 5C). Consistent with their abilities to enhance 
cisplatin uptake to a similar extent to the wild-type protein, 
expression of either H22-24A, NHA, H139R or Y156A variants 
increased cisplatin cytotoxicity by 1.9-, 2.1-, 1.7- and 2.1-folds, 
with IC50 of 102.9±12.1, 90.4±5.6, 115.2±5.2 and 93.9±4.1 μM, 
respectively. However, expression of either C189S or CT178 
rendered Hela cells less sensitive to platinum compared with that 
of the wild-type hCTR1, with the IC50 values of 131.2±20.1 and 
165.8±9.3 μM, respectively. Significantly, the correlation 
between cisplatin accumulation and cytotoxicity of the drug 
among hCTR1 variants expressed cells was noted, demonstrating 
that the drug accumulated by the exogenous hCTR1 was 
successfully transferred to the critical targets such as DNA.  
 
Fig. 5 Effects of mutations of hCTR1 on cisplatin accumulation and 
sensitivity towards the cytotoxicity of cisplatin in Hela cells (A) Total 
platinum accumulation upon exposure to 100 μM cisplatin for 10 mins. 
(B) Survival rates of Hela cells harboring empty vector (); the wild-type 
hCTR1 (); H22-24A (▲); NHA (▼); H139R (); Y156A (◄); 
C189S (►) and CT178 (), after exposure to increasing concentrations 
of cisplatin for 10 mins and then cultured in normal media for 96 hrs. (C) 
IC50 of cisplatin determined with Sigmoidal fitting. The error bars 
represent standard derivations from four independent experiments. The 
asterisk  indicates p<0.05 as determined by the Student’s t test, compared 
with the wild-type hCTR1. 
 Like in the case of copper, among all the variant forms of 
hCTR1 examined, only truncation at the C-terminus (CT178) 
completely abolished hCTR1 mediated cellular uptake of 
cisplatin, whereas the single mutation at Cys189 only partially 
reduced the cisplatin uptake. Therefore, the C-terminus of hCTR1 
is required for both the cellular uptake of copper and cisplatin. In 
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the absence of Cys189, the adjacent two His residues (H188 and 
H190) might serve as the coordination ligands for Cu(І) and 
probably Pt(II), as supported by the observation of Cu-N (His) 
coordination signal in the EXAFS spectra of hCTR1 when 
incubated with Cu+.13 According to our previous studies, cisplatin 
was presumed to be transported via hCTR1 in its monofunctional 
form (cis-[PtCl(NH3)2]
+).34 Thus, similar to Cu+, the 
monofunctional cisplatin is likely to pass through the pore created 
by three monomers of hCTR1 via a series of trans-chelation 
reactions between Met154 and Met150.13 The C-terminal Cys189 
(or 188HCH motif) may participate in the sequential trans-
chelation reactions, accepting copper and cisplatin from the upper 
ring probably formed by three Met150  and then handling them 
down.  
 The requirement of Met-rich motifs at the N-terminus of 
hCTR1 for cisplatin transport has been extensively studied,20 
however, the role of its His-rich motifs (3HXHH and 22HHH) was 
poorly understood.  We found mutations at the His-rich motifs 
did not affect the ability of hCTR1 to stimulate the cellular 
uptake of cisplatin, suggesting that these residues play a less 
important role in cisplatin transport. This is supported by the 
recent study showing that cisplatin binds predominately to the N-
terminus methionine residues but not histidine residues of 
hCTR1.34, 35 Recent electro-crystallographic analysis 
demonstrated that the second transmembrane helix of hCTR1 
serves as the key element lining the pore created by three 
monomers of hCTR1.13 Along the pore, Met154, Met150 and 
H139 were suggested to form three stacked rings which mediated 
copper influx through a series of trans-chelation reactions. 
Previously, intensive studies have demonstrated the importance 
of these three residues in hCTR1-mediated copper transport.20-22, 
25 We show here that the mutation of H139 to arginine decreased 
copper but not cisplatin accumulation in Hela cells, indicating 
that H139 of hCTR1 play little role in cisplatin transport, in 
agreement with a previous report that mutation of H139 to 
alanine (H139A) did not significantly affect its ability to transport 
cisplatin in Ctr1-/- MEF system.23 Similarly,  Y156 located at the 
second transmembrane segment plays an important role in the 
uptake of copper but not cisplatin in Hela cells. Previously, it was 
also observed an 80% reduction at the copper transport rate 
compared with that of the wild-type protein in Sf9 cells 
expressing the Y156A variant.25 This residue is located closely to 
Met154 and may structurally help to place Met154 appropriately. 
The discrepancy occurred for the these variants such in mediating 
copper and cisplatin uptake, possibly attributed to variation in the 
local structure or charge for these variant proteins. 
Conclusion 
The effect of hCTR1 mutations on cellular accumulation and 
sensitivity enhancement of cytotoxicity of both copper and Pt 
drugs was investigated. The necessity of the C-terminus of 
hCTR1 in cisplatin uptake was addressed in this report, which 
might shed light on the mechanism of cisplatin uptake. Our 
combined data suggested that despite of both copper and cisplatin 
passing through the trimeric pore of hCTR1 via a series of trans-
chelation reactions, the detailed molecular mechanism might be 
different. Further biological and structural investigations of the 
transport are therefore warranted. 
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